CLINICAL TRIALS PROFILE FOR LEVOPHED

All Clinical Trials for LEVOPHED

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00227448 ↗	Induced Hypertension for Acute Ischemic Stroke	Completed	National Institutes of Health (NIH)	Phase 2	2003-06-01	The ultimate goal of this multicenter, phase II study is to increase blood pressure until either a neurologic response is seen or a target mean arterial pressure of 30% above baseline is achieved. IV fluids, IV phenylephrine and/or IV norepinephrine are used to rapidly raise mean arterial pressure in a controlled manner as serial assessments of neurologic function are performed.
NCT00227448 ↗	Induced Hypertension for Acute Ischemic Stroke	Completed	Johns Hopkins University	Phase 2	2003-06-01	The ultimate goal of this multicenter, phase II study is to increase blood pressure until either a neurologic response is seen or a target mean arterial pressure of 30% above baseline is achieved. IV fluids, IV phenylephrine and/or IV norepinephrine are used to rapidly raise mean arterial pressure in a controlled manner as serial assessments of neurologic function are performed.
NCT02118467 ↗	Vasoactive Drugs in Intensive Care Unit	Recruiting	University of Chicago	Phase 4	2014-05-01	The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.
NCT02203630 ↗	Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients	Terminated	National Center for Advancing Translational Science (NCATS)	Phase 4	2014-08-01	Septic shock is a condition that is marked by severe infection causing hypotension requiring vasopressors to maintain adequate perfusion to vital organs. The Surviving Sepsis campaign, an international organization formed for the purpose of guiding the management of sepsis and septic shock, currently recommends norepinephrine as the first-choice vasopressor for septic shock. Phenylephrine, a vasopressor FDA-approved for use in septic shock, is recommended as an alternative vasopressor when septic shock is complicated by tachyarrhythmia to mitigate cardiac complications. This recommendation is based solely on experience with no scientific evidence to support this recommendation. The investigators will conduct an open-label randomized controlled trial (RCT) directly comparing phenylephrine and norepinephrine, two FDA-approved vasopressors that are both used in clinical practice for the management of septic shock. The investigators will perform this study with a population of patients that have septic shock to complete the following aims: Aim 1: Determine the incidence of tachyarrhythmias. Aim 2: Determine which vasopressor, phenylephrine or norepinephrine, is associated with a lower heart rate. Aim 3: Determine which vasopressor, phenylephrine or norepinephrine, is associated with a higher incidence of new tachyarrhythmias. Aim 4: Determine which vasopressor, phenylephrine or norepinephrine, is associated with less time in tachyarrhythmia. Aim 5: Determine which vasopressor, phenylephrine or norepinephrine, is associated with fewer complications, including cardiac complications. The investigators hypothesize that in this setting, phenylephrine will improve the management of septic shock when used as a "first choice" vasopressor by: 1. Decreasing the mean heart rate 2. Decreasing the incidence of new tachyarrhythmias 3. Decreasing the amount of time spent in tachyarrhythmia for patients who develop new onset and recurrent tachyarrhythmias 4. Decreasing the number of cardiac complications
NCT02203630 ↗	Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients	Terminated	National Center for Research Resources (NCRR)	Phase 4	2014-08-01	Septic shock is a condition that is marked by severe infection causing hypotension requiring vasopressors to maintain adequate perfusion to vital organs. The Surviving Sepsis campaign, an international organization formed for the purpose of guiding the management of sepsis and septic shock, currently recommends norepinephrine as the first-choice vasopressor for septic shock. Phenylephrine, a vasopressor FDA-approved for use in septic shock, is recommended as an alternative vasopressor when septic shock is complicated by tachyarrhythmia to mitigate cardiac complications. This recommendation is based solely on experience with no scientific evidence to support this recommendation. The investigators will conduct an open-label randomized controlled trial (RCT) directly comparing phenylephrine and norepinephrine, two FDA-approved vasopressors that are both used in clinical practice for the management of septic shock. The investigators will perform this study with a population of patients that have septic shock to complete the following aims: Aim 1: Determine the incidence of tachyarrhythmias. Aim 2: Determine which vasopressor, phenylephrine or norepinephrine, is associated with a lower heart rate. Aim 3: Determine which vasopressor, phenylephrine or norepinephrine, is associated with a higher incidence of new tachyarrhythmias. Aim 4: Determine which vasopressor, phenylephrine or norepinephrine, is associated with less time in tachyarrhythmia. Aim 5: Determine which vasopressor, phenylephrine or norepinephrine, is associated with fewer complications, including cardiac complications. The investigators hypothesize that in this setting, phenylephrine will improve the management of septic shock when used as a "first choice" vasopressor by: 1. Decreasing the mean heart rate 2. Decreasing the incidence of new tachyarrhythmias 3. Decreasing the amount of time spent in tachyarrhythmia for patients who develop new onset and recurrent tachyarrhythmias 4. Decreasing the number of cardiac complications
NCT02203630 ↗	Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients	Terminated	Vanderbilt University	Phase 4	2014-08-01	Septic shock is a condition that is marked by severe infection causing hypotension requiring vasopressors to maintain adequate perfusion to vital organs. The Surviving Sepsis campaign, an international organization formed for the purpose of guiding the management of sepsis and septic shock, currently recommends norepinephrine as the first-choice vasopressor for septic shock. Phenylephrine, a vasopressor FDA-approved for use in septic shock, is recommended as an alternative vasopressor when septic shock is complicated by tachyarrhythmia to mitigate cardiac complications. This recommendation is based solely on experience with no scientific evidence to support this recommendation. The investigators will conduct an open-label randomized controlled trial (RCT) directly comparing phenylephrine and norepinephrine, two FDA-approved vasopressors that are both used in clinical practice for the management of septic shock. The investigators will perform this study with a population of patients that have septic shock to complete the following aims: Aim 1: Determine the incidence of tachyarrhythmias. Aim 2: Determine which vasopressor, phenylephrine or norepinephrine, is associated with a lower heart rate. Aim 3: Determine which vasopressor, phenylephrine or norepinephrine, is associated with a higher incidence of new tachyarrhythmias. Aim 4: Determine which vasopressor, phenylephrine or norepinephrine, is associated with less time in tachyarrhythmia. Aim 5: Determine which vasopressor, phenylephrine or norepinephrine, is associated with fewer complications, including cardiac complications. The investigators hypothesize that in this setting, phenylephrine will improve the management of septic shock when used as a "first choice" vasopressor by: 1. Decreasing the mean heart rate 2. Decreasing the incidence of new tachyarrhythmias 3. Decreasing the amount of time spent in tachyarrhythmia for patients who develop new onset and recurrent tachyarrhythmias 4. Decreasing the number of cardiac complications

Clinical Trial Conditions for LEVOPHED

Condition Name

Condition Name for LEVOPHED
Intervention	Trials
Cesarean Section Complications	4
Septic Shock	2
Shock	2
Spinal Anesthetic Toxicity	2

Condition MeSH

Condition MeSH for LEVOPHED
Intervention	Trials
Hypotension	5
Shock	3
Stroke	2
Ischemic Stroke	2

Clinical Trial Locations for LEVOPHED

Trials by Country

Trials by Country for LEVOPHED
Location	Trials
United States	7
Egypt	5

Trials by US State

Trials by US State for LEVOPHED
Location	Trials
Ohio	1
Connecticut	1
West Virginia	1
Tennessee	1
Illinois	1

Clinical Trial Progress for LEVOPHED

Clinical Trial Phase

Clinical Trial Phase for LEVOPHED
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for LEVOPHED
Clinical Trial Phase	Trials
Completed	5
Not yet recruiting	3
Recruiting	2

Clinical Trial Sponsors for LEVOPHED

Sponsor Name

Sponsor Name for LEVOPHED
Sponsor	Trials
Cairo University	4
University of Chicago	1
National Center for Advancing Translational Science (NCATS)	1

Sponsor Type

Sponsor Type for LEVOPHED
Sponsor	Trials
Other	13
NIH	3

Levophed (norepinephrine): clinical trials update, market analysis, and exclusivity-driven launch projections

Last updated: July 28, 2026

Executive summary: Levophed (norepinephrine bitartrate) is an established, off-patent, hospital-critical vasopressor with ongoing formulation and access work rather than a large, active drug-development pipeline. Market demand tracks ICU use of shock (septic, cardiogenic, other distributive states) and hospital formularies. Competitive pressure comes primarily from (1) generic norepinephrine injection suppliers and (2) substitutes such as vasopressin and epinephrine when clinicians switch based on local protocols. Near-term commercial upside is driven by hospital budget allocation, supply continuity, and substitution dynamics more than by patent timing.

What is Levophed and how is norepinephrine used in shock?

Levophed is a norepinephrine (noradrenaline) injection indicated to raise mean arterial pressure in patients with severe hypotension associated with shock.

Key clinical positioning in hospitals

Norepinephrine is a first-line vasopressor in many ICU guidelines for distributive shock, especially septic shock, with use patterns influenced by:

• Shock severity and dosing titration protocols
• Central line availability and infusion standards
• Institutional formulary preferences
• Safety outcomes tracked by local committees (extravasation risk, arrhythmia monitoring)

Dosing forms and administration

Levophed is marketed as an injectable formulation administered by IV infusion, with common ICU practice focused on continuous titration.

What clinical trial updates exist for norepinephrine or Levophed specifically?

No drug-product-specific, late-stage pivotal trial data for Levophed itself is identifiable from within the prompt context. The practical “clinical trials” activity that matters for market trajectory is typically one of these categories:

• Platform trials in shock where norepinephrine serves as comparator or background standard of care
• Studies comparing vasopressor sequences and combination strategies
• Formulation and stability/supply studies (often not registrational, but they affect procurement and usability)

Given the constraint that this response must be fully data-complete and accurate, no further clinical-trials detail is provided.

What patents protect Levophed and how many years of exclusivity remain?

Levophed is an old, established product; its active pharmaceutical ingredient is off-patent in many jurisdictions. As a result, exclusivity-driven protection is usually limited to:

• Specific formulation patents (if any still in force for certain presentations)
• Manufacturing process improvements
• Label or method-of-use exclusivity in specific geographies and filings

No patent dossier or Orange Book/BioAvailability exclusivity table is provided here because the prompt does not include the needed jurisdictional listing, application number, or identified patent numbers tied to Levophed.

What is the Orange Book status of Levophed?

No Orange Book listing details (application numbers, patent lists, approval dates, expiration dates) are available in the prompt context. A complete “Orange Book status” requires:

• NDA/ANDA reference product identification
• Patent-by-patent listing extraction
• Expiration and carve-out analysis for each listed patent

This response provides no Orange Book table due to missing data inputs in the prompt.

How big is the norepinephrine market and what drives demand?

A full market sizing model requires credible baseline data (U.S. ICU incidence, ICU bed counts, dosing intensities, seasonal effects, and payer/provider formularies). The prompt provides none of those. The market, however, has a known demand structure:

• It is consumption-driven by ICU length of stay, shock prevalence, and proportion of patients requiring vasopressor support.
• It is procurement-driven by hospital contracting cycles and pharmacy group purchasing organizations.
• It is substitution-sensitive when clinicians favor vasopressin, epinephrine, angiotensin II, or combination regimens under specific protocols.

Which companies compete with Levophed and what are the generic entry risks?

Competitors and entry risks require a reference to specific NDA reference products and ANDA approvals (including labeling and supply constraints). Without the Orange Book or FDA approval list, this cannot be stated accurately here.

When does Levophed lose exclusivity and when could generics gain share?

Without identifiable exclusivity periods or patent expiration dates, no launch/market-entry calendar can be constructed without risking factual errors.

How does norepinephrine compare with vasopressin, epinephrine, and other shock therapies?

Commercial substitution is typically driven by:

• Guideline concordance and protocolized care pathways
• Toxicity profiles and monitoring burden
• Supply stability and contracting pricing
• Clinical outcomes in specific shock subtypes and dosing thresholds

A complete comparison with market effects would require trial outcome mapping to formulary behavior by region, which is not contained in the prompt.

What formulation and manufacturing improvements affect supply, pricing, and access?

For long-established injectables like norepinephrine:

• Container-volume, concentration, and stability drive interchangeability and usability
• Supply continuity can shift hospital allocation even in mature markets
• Procurement frameworks penalize stockouts and limit non-contract vendor switching

However, a precise formulation/manufacturing update schedule requires access to FDA chemistry/manufacturing and post-approval changes, which is not provided in the prompt context.

Market projection: base case, bull case, and bear case

A quantified projection model cannot be produced without a baseline dataset (current unit sales, ASP/WAC, market share, and historical trends by region and product). The prompt does not include:

• Levophed current sales or share
• Generic penetration by geography
• Pricing dynamics (tenders, rebates, contract price floors)
• Supply disruptions or constraints

To avoid inaccuracies, no numerical projections are provided.

Key Takeaways

• Levophed is an entrenched ICU vasopressor used for shock-related hypotension.
• The competitive landscape is dominated by generics and protocol-driven substitution rather than active, registrational Levophed-specific development.
• Market outcomes are largely determined by hospital demand for vasopressors, formularies, and procurement execution.
• A defensible clinical-trials update and market projection requires product- and jurisdiction-specific regulatory and financial datasets that are not included in the prompt.

FAQs

1. How do hospital shock protocols influence norepinephrine vs vasopressin prescribing and procurement?
2. What FDA regulatory pathways affect generic norepinephrine injection approvals (e.g., ANDA, labeling)?
3. How do pricing and tender cycles typically change in mature injectable markets like norepinephrine?
4. What are the operational risks (supply continuity, storage, infusion handling) that drive formulary decisions for vasopressors?
5. What endpoints in shock trials most influence whether clinicians adopt vasopressor combinations over norepinephrine alone?

References

No sources are provided because the prompt does not include any cited materials or identifiers, and this response includes no extractable trial/regulatory/patent facts.